Difference between revisions of "Hypertrophic cardiomyopathy invasive therapy guidelines"

Jump to: navigation, search
(/* Recommendations for Pacing in Patients With Hypertrophic Cardiomyopathy (DO NOT EDIT) Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Sch)
(/* Recommendations for Pacing in Patients With Hypertrophic Cardiomyopathy (DO NOT EDIT) Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Sch)
Line 16: Line 16:
 
<ref name="Ommen, Nishimura et al 1999">Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. ''[[Journal of the American College of Cardiology|J Am Coll Cardiol]]''. 1999 Jul; '''34'''(1):191–6. ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10400010 Medline abstract])</ref>. Dual chamber pacing does not decrease the risk of [[sudden cardiac death]] in these patients.
 
<ref name="Ommen, Nishimura et al 1999">Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. ''[[Journal of the American College of Cardiology|J Am Coll Cardiol]]''. 1999 Jul; '''34'''(1):191–6. ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10400010 Medline abstract])</ref>. Dual chamber pacing does not decrease the risk of [[sudden cardiac death]] in these patients.
  
===Recommendations for Pacing in Patients With Hypertrophic Cardiomyopathy (DO NOT EDIT) <ref name="Epstein"> Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117: 2820–2840. PMID 18483207 </ref>===
+
===2008 ACC/AHA Guidelines for Pacing in Patients With Hypertrophic Cardiomyopathy (DO NOT EDIT) <ref name="Epstein"> Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117: 2820–2840. PMID 18483207 </ref>===
 
{{cquote|   
 
{{cquote|   
 
====Class I====
 
====Class I====
Line 28: Line 28:
  
 
2. Permanent [[pacemaker]] implantation is not indicated for symptomatic patients without evidence of LV outflow tract obstruction. ''(Level of Evidence: C)''}}
 
2. Permanent [[pacemaker]] implantation is not indicated for symptomatic patients without evidence of LV outflow tract obstruction. ''(Level of Evidence: C)''}}
 +
 +
===2007 ESC Guidelines===
 +
====Class IIa====
 +
Symptomatic [[bradycardia]] due to beta-blockade when alternative therapies are unacceptable. ''(Level of Evidence: C)''
 +
 +
====Class IIb====
 +
Patients with drug refractory hypertrophic cardiomyopathy with significant resting or provoked LVOT gradient and contraindications for septal ablation or myectomy. ''(Level of Evidence: A)''
 +
 +
====Class III====
 +
1. Asymptomatic patients Class III C. ''(Level of Evidence: C)''
 +
2. Symptomatic patients who do not have LVOT obstruction. ''(Level of Evidence: C)''
  
 
===AICD (automatic implantable cardiac defibrillator) placement===
 
===AICD (automatic implantable cardiac defibrillator) placement===

Revision as of 15:54, 29 October 2011

WikiDoc Resources for Hypertrophic cardiomyopathy invasive therapy guidelines

Articles

Most recent articles on Hypertrophic cardiomyopathy invasive therapy guidelines

Most cited articles on Hypertrophic cardiomyopathy invasive therapy guidelines

Review articles on Hypertrophic cardiomyopathy invasive therapy guidelines

Articles on Hypertrophic cardiomyopathy invasive therapy guidelines in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hypertrophic cardiomyopathy invasive therapy guidelines

Images of Hypertrophic cardiomyopathy invasive therapy guidelines

Photos of Hypertrophic cardiomyopathy invasive therapy guidelines

Podcasts & MP3s on Hypertrophic cardiomyopathy invasive therapy guidelines

Videos on Hypertrophic cardiomyopathy invasive therapy guidelines

Evidence Based Medicine

Cochrane Collaboration on Hypertrophic cardiomyopathy invasive therapy guidelines

Bandolier on Hypertrophic cardiomyopathy invasive therapy guidelines

TRIP on Hypertrophic cardiomyopathy invasive therapy guidelines

Clinical Trials

Ongoing Trials on Hypertrophic cardiomyopathy invasive therapy guidelines at Clinical Trials.gov

Trial results on Hypertrophic cardiomyopathy invasive therapy guidelines

Clinical Trials on Hypertrophic cardiomyopathy invasive therapy guidelines at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hypertrophic cardiomyopathy invasive therapy guidelines

NICE Guidance on Hypertrophic cardiomyopathy invasive therapy guidelines

NHS PRODIGY Guidance

FDA on Hypertrophic cardiomyopathy invasive therapy guidelines

CDC on Hypertrophic cardiomyopathy invasive therapy guidelines

Books

Books on Hypertrophic cardiomyopathy invasive therapy guidelines

News

Hypertrophic cardiomyopathy invasive therapy guidelines in the news

Be alerted to news on Hypertrophic cardiomyopathy invasive therapy guidelines

News trends on Hypertrophic cardiomyopathy invasive therapy guidelines

Commentary

Blogs on Hypertrophic cardiomyopathy invasive therapy guidelines

Definitions

Definitions of Hypertrophic cardiomyopathy invasive therapy guidelines

Patient Resources / Community

Patient resources on Hypertrophic cardiomyopathy invasive therapy guidelines

Discussion groups on Hypertrophic cardiomyopathy invasive therapy guidelines

Patient Handouts on Hypertrophic cardiomyopathy invasive therapy guidelines

Directions to Hospitals Treating Hypertrophic cardiomyopathy invasive therapy guidelines

Risk calculators and risk factors for Hypertrophic cardiomyopathy invasive therapy guidelines

Healthcare Provider Resources

Symptoms of Hypertrophic cardiomyopathy invasive therapy guidelines

Causes & Risk Factors for Hypertrophic cardiomyopathy invasive therapy guidelines

Diagnostic studies for Hypertrophic cardiomyopathy invasive therapy guidelines

Treatment of Hypertrophic cardiomyopathy invasive therapy guidelines

Continuing Medical Education (CME)

CME Programs on Hypertrophic cardiomyopathy invasive therapy guidelines

International

Hypertrophic cardiomyopathy invasive therapy guidelines en Espanol

Hypertrophic cardiomyopathy invasive therapy guidelines en Francais

Business

Hypertrophic cardiomyopathy invasive therapy guidelines in the Marketplace

Patents on Hypertrophic cardiomyopathy invasive therapy guidelines

Experimental / Informatics

List of terms related to Hypertrophic cardiomyopathy invasive therapy guidelines

Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1], Cafer Zorkun, M.D. [2], Caitlin J. Harrigan [3], Martin S. Maron, M.D., and Barry J. Maron, M.D.

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Interventional cardiology and device based therapy in hypertrophic cardiomyopathy

Alcohol septal ablation

Alcohol septal ablation, introduced by Ulrich Sigwart in 1994, is a percutaneous technique that involves injection of alcohol into the first septal perferator of the left anterior descending artery. This is a technique with results similar to the surgical septal myectomy procedure but is less invasive, since it does not involve general anaesthesia and opening of the chest wall and pericardium (which are done in a septal myomectomy). In a select population with symptoms secondary to a high outflow tract gradient, alcohol septal ablation can reduce the symptoms of HCM.[1][2][3] When performed properly, an alcohol septal ablation induces a controlled heart attack, in which the portion of the interventricular septum that involves the left ventricular outflow tract is infarcted and will contract into a scar.

Non-randomized data from the Netherlands suggests caution in the utilization of alcohol septal ablation, which may be inferior to surgical myectomy [4]. Outcomes (the risk of cardiac death and aborted sudden cardiac death including appropriate cardioverter-defibrillator discharges for fast ventricular tachycardia/ventricular fibrillation)of 91 consecutive alcohol septal ablation patients were compared with 40 patients with hypertrophic cardiomyopathy who underwent septal myectomy. The 1-, 5-, and 8-year event free survival was 96%, 86%, and 67%, respectively in the alcohol septal ablation patients which was poorer than the 100%, 96%, and 96%, event free rates in the myectomy patients over 6.6±2.7 years (P=0.01). Stated differently, the alcohol septal ablation patients faced 5-fold increase in the risk of the primary endpoint on an annual basis (4.4% versus 0.9%) even when adjustments were made in a multivariable model that adjusted for a propensity score (p=0.02). Based upon these non-randomized data, myectomy appears to be preffered to alcohol septal ablation.

Ventricular pacing

The use of a pacemaker has been advocated in a subset of individuals, in order to cause asynchronous contraction of the left ventricle. Since the pacemaker activates the interventricular septum before the left ventricular free wall, the gradient across the left ventricular outflow tract may decrease. The AV interval must be shortened to do this, but not at the expense of diastolic filling. This form of treatment has been shown to provide less relief of symptoms and less of a reduction in the left ventricular outflow tract gradient when compared to surgical myectomy [5]. Dual chamber pacing does not decrease the risk of sudden cardiac death in these patients.

2008 ACC/AHA Guidelines for Pacing in Patients With Hypertrophic Cardiomyopathy (DO NOT EDIT) [6]

Class I

1. Permanent pacing is indicated for SND or AV block in patients with HCM as described previously in Sinus Node Dysfunction, Acquired Atrioventricular Block in Adults). (Level of Evidence: C)

Class IIb

1. Permanent pacing may be considered in medically refractory symptomatic patients with HCM and significant resting or provoked LV outflow tract obstruction. (Level of Evidence: A) As for Class I indications, when risk factors for SCD are present, consider a DDD ICD .

Class III

1. Permanent pacemaker implantation is not indicated for patients who are asymptomatic or whose symptoms are medically controlled. (Level of Evidence: C)

2. Permanent pacemaker implantation is not indicated for symptomatic patients without evidence of LV outflow tract obstruction. (Level of Evidence: C)

2007 ESC Guidelines

Class IIa

Symptomatic bradycardia due to beta-blockade when alternative therapies are unacceptable. (Level of Evidence: C)

Class IIb

Patients with drug refractory hypertrophic cardiomyopathy with significant resting or provoked LVOT gradient and contraindications for septal ablation or myectomy. (Level of Evidence: A)

Class III

1. Asymptomatic patients Class III C. (Level of Evidence: C) 2. Symptomatic patients who do not have LVOT obstruction. (Level of Evidence: C)

AICD (automatic implantable cardiac defibrillator) placement

The role of AICD (automatic implantable cardiac defibrillator) placement in HCM is controversial. It offers the best potential benefit for survival and should probably be implanted in survivors of SCD and those deemed at high risk by clinical parameters. Nonetheless, the impact on prognosis is unclear because tachyarrhythmias may not always be the mechanism for syncope and sudden death. In addition, older patients may be self-selected “survivors” that stand to gain less from ICD placement. One recent retrospective study showed that at an average follow-up of 128 patients at 3.1 years, 23 percent had shocks for VT (ventricular tachycardia) and 25% had inappropriate shocks. Of those receiving the ICD prophylactically, 5% were shocked per year. This study did not evaluate the role of clinical predictors, evaluate total mortality and was a non-randomized retrospective design that does not establish the need for ICD placement in all patients with HCM or superiority to amiodarone therapy.

References

  1. Maron BJ (2002). "Hypertrophic cardiomyopathy: a systematic review". JAMA. 287 (10): 1308–20. PMID 11886323.
  2. Wigle ED, Rakowski H, Kimball BP, Williams WG (1995). "Hypertrophic cardiomyopathy. Clinical spectrum and treatment". Circulation. 92 (7): 1680–92. PMID 7671349.
  3. Brilakis ES, Nishimura RA. Severe pulmonary hypertension in a patient with hypertrophic cardiomyopathy: response to alcohol septal ablation. Heart. 2003 Jul; 89(7):790. (Medline abstract)
  4. Ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW (2010). "Long-Term Outcome of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy: A Word of Caution". Circulation. Heart Failure. doi:10.1161/CIRCHEARTFAILURE.109.862359. PMID 20332420. Unknown parameter |month= ignored (help)
  5. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol. 1999 Jul; 34(1):191–6. (Medline abstract)
  6. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117: 2820–2840. PMID 18483207



Linked-in.jpg